5α降解酶抑制剂和前列腺癌死亡率
Robert J Hamilton1,2, Julian Chavarriaga1, Najia Khurram1
1Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
JAMA network open
|August 27, 2024
概括
这项研究发现,在前列腺癌 (PCa) 诊断之前使用的5-α-减少酶抑制剂 (5-ARIs) 不会增加整体或PCa特定的死亡率. 这些发现为使用5-ARI治疗良性前列腺增生或预防癌症的患者提供了保证.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 5α-减少酶抑制剂 (5-ARIs) 已被批准用于良性前列腺增生 (BPH) 并降低前列腺癌 (PCa) 风险.
- 然而,对于可能增加高等级PCa的5-ARIs及其对诊断患者死亡率的影响存在担忧.
研究的目的:
- 为了研究与非使用者相比,在诊断前使用5 - ARI的临床局部PCa的男性的长期死亡结果.
主要方法:
- 在加拿大安大略省 (2003-2017) 进行的一项基于人口的队列研究包括19938名65岁以上的男性,他们有局部PCa.
- 治疗权重的逆概率 (IPTW) 用于分析预诊断的5-ARI使用和整体/PCa特定死亡率之间的关联.
主要成果:
- 在19,938名患者中,2,112人使用了5-ARIs. 在8.96年的中位数随访期间,死亡人数为6,053人.
- 在IPTW调整后,5-ARI使用与增加的整体死亡率 (HR 0.98;95% CI 0.90-1.07) 或PCa特定死亡率 (HR 1.02;95% CI 0.83-1.25) 没有显著关联.
结论:
- 在男性局部PCa中预诊断的5-ARI使用与PCa特定或全因死亡率的增加无关.
- 这项研究为BPH或化疗预防的PCa诊断之前的5-ARI使用提供了令人放心的安全数据.
相关概念视频
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
561
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
561
01:20Disorders of the Male Reproductive System
365
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
365
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
138
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
138
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:25Antihypertensive Drugs: Direct Renin Inhibitors
512
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
512
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162